A Phase 2, Open Label Study of Rucaparib in Patients With Advanced Pancreatic Cancer and a Known Deleterious Germline or Somatic BRCA or PALB2 Mutation
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Rucaparib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 27 Oct 2017 Planned End Date changed from 1 May 2022 to 1 Jun 2022.
- 27 Oct 2017 Planned primary completion date changed from 1 May 2021 to 30 Jun 2021.
- 08 May 2017 New trial record